Update on future headache treatments

Neurological Sciences

Volumn 34, Issue SUPPL. 1, 2013, Pages

  Nagy, Abraham J ^a,b   Rapoport, Alan M ^a,c  

^a Nevada Headache institute   (United States)

^b K e Centers for Advanced Medicine LLC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute migraine treatment; CGRP antagonist; Dihydroergotamine; Headache therapy pipeline

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; ANTIMIGRAINE AGENT; BI 44370; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CIS CAPSAICIN; DIHYDROERGOTAMINE MESILATE; GLUTAMATE RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; KETAMINE; LASMIDITAN; MEMANTINE; NITRIC OXIDE; OLCEGEPANT; OREXIN RECEPTOR ANTAGONIST; PLACEBO; PROSTANOID RECEPTOR ANTAGONIST; RIMEGEPANT; SEROTONIN AGONIST; SUMATRIPTAN SUCCINATE; SUVOREXANT; TELCAGEPANT; TEZAMPANEL; TONABERSAT; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANILLOID RECEPTOR; VANILLOID RECEPTOR 1 ANTAGONIST; ZOLMITRIPTAN;

ANALGESIA; ARTICLE; DIZZINESS; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSGEUSIA; FATIGUE; GAP JUNCTION; HEADACHE; HUMAN; METALLIC TASTE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NERVE STIMULATION; RECEPTOR AFFINITY; SOMNOLENCE; SPHENOPALATINE GANGLION INTERMITTENT STIMULATION; TRANSDERMAL PATCH; VERTIGO; NEUROLOGY; REVIEW; TRENDS;

HEADACHE; HUMANS; NEUROLOGY; PAIN MANAGEMENT;

EID: 84892502598     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-013-1396-7     Document Type: Article

References (71)

1. Johnston M, Rapoport A (2010) Triptans for the management of migraine. Drugs 70:1505-1518
2. Bigal M, Rapoport A, Aurora S et al (2007) Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 47:475-479
3. Pierce M, Marbury T, O'Neill C et al (2009) Zelrix: a novel transdermal formulation of sumatriptan. Headache 49:817-825
4. Goldstein J, Smith TR, Pugach N et al (2012) A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 52:1402-1410. doi:10.1111/j.1526-4610.2012.02198.x
5. Smith TR, Goldstein J, Singer R et al (2012) Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache 52:612-624. doi: 10.1111/j.1526-4610.2012.02094.x
6. Luthringer R, Djupesland PG, Sheldrake CD et al (2009) Rapid absorption of sumatriptan powder and effects on the glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol 61:1219-1228
7. Djupesland PG, Dočekal P (2010) Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 30:933-942
8. Boureau F, Kappos L, Schoenen J, Esperanca P, Ashford E (2010) A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract 54:281-286
9. Armer T, Shrewsbury S, Newman S et al (2007) Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 23:3177-3187
10. Shrewsbury S, Cook R, Taylor G et al (2008) Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO) inhaler. Headache 48:355-367
11. Aurora SK, Silberstein SD, Kori SH et al (2011) MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 51:507-517
12. Goadsby PJ, Edvinsson L (1993) The trigemino vascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48-56
13. Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104-1110
14. Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304-1312
15. Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and to-lerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2089-2090
16. Tepper SJ, Cleves C (2009) Telcagepant, a calcitonin generelated peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs 10:711-720
17. Diener HC, Barbanti P, Dahlöf C et al (2011) BI 44370TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a Phase II study. Cephalalgia 31:573-584
18. Study to evaluate the PK of BMS-927711 in patients with migraine during acute migraine and non-migraine condition. NCT01445067 http://clinicaltrials. gov/ct2/show/NCT01445067 (accessed 2 Feb 2013)
19. BehmMO,BlanchardRL,MurphyMG, Chodakewitz JA, Palcza JS, Harris DE et al (2008) Assessment of the effect ofMK-0974, an oral CGRP receptor antagonist, on spontaneous ischemia in patients with stable cardiovascular disease [abstract]. Headache 48:S39
20. Viallalon CM, Centurion D, Valdicia LF et al (2002) An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc 45:199-210
21. Neeb L, Meents J, Reuter U (2010) 5-HT1F receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics 7:176-182
22. Färkkilä M, Diener H, Géraud G et al (2010) Lasmiditan (COL-144), a selective 5HT1F agonist, is a rapid and effective oral treatment for acute migraine. J Headache Pain 11:S43
23. Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J et al (1999) Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 19:851-858
24. Nelson DL, Phebus LA, Johnson KW (2010) Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan. Cephalalgia 30:1159-1169
25. Tfelt-Hansen PC, Olesen J (2012) The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 13:271-275
26. Schytz H, Barløse M, Guo S, et al. (2013) Experimental activation of the sphenopalatine ganglion provokes cluster-like attacks in humans. Cephalalgia. doi: 10.1177/0333102413476370
27. Ansarinia M, Rezai A, Tepper S et al (2010) Electrical stimulation of sphenopalatine ganglion for acute treatment of cluster headaches. Headache 50:1164-1174
28. Schoenen J, Jensen R, Lanteri-Minet M, et al. (2013) Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. doi: 10.1177/0333102412473667
29. Tepper SJ, Rezai A, Narouze S et al (2009) Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache 49:983-989
30. Jansen-Olesen I, Mortensen A, Edvinsson L (1996) Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16:310-316
31. Rapoport A (2012) The therapeutic future in headache. Neurol Sci 33:S119-S125
32. Saper J, Klapper J, MathewNet al (2002) Intransal civamide for the treatment of episodic cluster headaches. Arch Neurol 59:990-994
33. Civamide nasal solution for cluster headache (ECH). NCT 01341548. http://clinicaltrials.gov/ct2/show/NCT01341548 (accessed 2 Feb 2013)
34. Diamond S, Freitag F, Philips SB et al (2000) Intranasal civamide for the acute treatment of migraine headache. Cephalalgia 20:597-602
35. Voight EA, Kort ME (2010) Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature. Expert Opin Ther Pat 20:1107-1122
36. Use of SB-705498 in the acute treatment of migraine. NCT00269022. http://www.clinicaltrials.gov/ct2/show/NCT00269022 (accessed 2 Feb 2013)
37. Iversen HK, Olesen J, Tfelt-Hansen P (1989) Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 38:17-24
38. Thomsen L, Kruuse C, Iversen H, Olesen J (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur Neurol 1:73-80
39. Olesen J, Thomsen LL, Iversen HK (1994) Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 15:149-153
40. Wei EP, Moskowitz MA, Boccalini P, Kontos HA (1992) Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ Res 70:1313-1319
41. Griffith OW, Kilbourn RG (1996) Nitric oxide synthase inhibitors: amino acids. Methods Enzymol 268:375-392
42. Lassen LH, Ashina M, Christiansen I et al (1998) Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 18:27-32
43. Høivik HO, Laurijssens BE, Harnisch LO et al (2010) Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30:1458-1467
44. Vaughan D, Speed J, Medve R, Andrews JS (2010) Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, doubleblind, parallel studies in healthy adult volunteers. Clin Ther 32:146-160
45. Medve RL, Lategan TW (2010) Assessment of the safety and tolerability of NXN-188 dihydrochloride in healthy volunteers and migraineurs. J Headache Pain 11:S37
46. Hadjikhani N, Sanchez Del Rio M, Wu O et al (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Prac Nat Acad Sci USA 98:4687-4692
47. Olesen J, Larsen B, Lauritzen M (1981) Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 9:344-352
48. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz M (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59:652-661
49. Read SJ, Smith MI, Hunter AJ, Upton N, Parsons AA (2000) SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 20:92-99
50. Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J (2009) Effects of tonabersat on migraine with aura: a randomised, doubleblind, placebo-controlled crossover study. Lancet Neurol 8:718-723
51. Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG (2009) Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 29:742-750
52. Minster Pharmaceuticals. News & media (2009) TEMPUS study results in migraine prevention. http://www.minsterpharma.com/news-463.asp (accessed 8 Jan 2010)
53. Dahlöf C, Hauge A, Olesen J (2009) Efficacy and safety of tonabersat, a gapjunction modulator, in the acute treatment of migraine: a double-blind, parallelgroup, randomized study. Cephalalgia 29:S7-S16
54. Silberstein S, Schoenen J, Gobel H et al (2009) Tonabersat, a gap-junctionmodulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia 29:S17-S27
55. Johnson KW, Nisenbaum ES, Johnson MP et al (2008) Innovative drug development for headache disorders: glutamate. In: Olesen J, Ramadan NM (eds) Frontiers in Headache Research. United States, New York, pp 185-194
56. Gorji A, Scheller D, Straub H et al (2001) Spreading depression in human neocortical slices. Brain Res 906:74-83
57. Kaube H, Herzog J, Käufer T et al (2000) Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55:139-141
58. Charles A, Flippen C (2007) Romero Reyes M, Brennan KC, Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain 8:248-250
59. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S (2008) Memantine in the preventive treatment of refractory migraine. Headache 48:1337-1342
60. Sang CN, Ramadan NM, Wallihan RG et al (2004) LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well tolerated in acute migraine. Cephalalgia 24:596-602
61. Raptor Pharmaceutical Corp. announces positive data on NGX426 in the potential treatment of neuropathic pain http://ir.raptorpharma.com/ releasedetail.cfm?ReleaseID=633925 (accessed 2.Feb 2013)
62. Efficacy and safety of BGG492 in the treatment of migraine. NCT00892203. http://clinicaltrials.gov/ct2/show/NCT00892203 (accessed Feb 2, 2013)
63. Marin JC, Goadsby PJ (2010) Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Expert Opin Investig Drugs 19:555-561
64. Bartsch T, Levy MJ, Knight YE, Goadsby PJ (2004) Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 109:367-378
65. Holland PR, Akerman S, Goadsby PJ (2006) Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 24:2825-2833
66. Holland P, Akerman S, Goadsby P (2006) Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 24:2825-2833
67. Winrow CJ, Gotter AL, Cox CD et al (2012) Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology 62:978-987
68. A study of the safety and efficacy of MK-6096 for migraine prophylaxis in participants with episodic migraine (MK-6096-020). NCT01513291. http://clinicaltrials.gov/ct2/show/NCT01513291 (accessed 2 Feb 2013)
69. Jenkins DW, Feniuk W, Humphrey PP (2001) Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol 134:1296-1302
70. Sarchielli P, Alberti A, Codini M et al (2000) Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20:907-918
71. Wienecke T, Olesen J, Oturai PS, Ashina M (2009) Prostaglandin E2 (PGE2) induces headache in healthy subjects. Cephalalgia 29:509-519